ClinicalTrials.gg
Not yet recruitingNCT07944716Updated Nov 18, 2026

Function-Friendly Semi-Fowler Positioning for Coronary Angiography and PCI

An interventional study of Function-Friendly Semi-Fowler Positioning in Coronary Disease, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Other

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 224 studies in Coronary Disease with a site in China — 69 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
140th of 142
10 · median 220
Started
2026
with 15 others
No phase
87 of 224
28 open now
Primary completion
2028-05
later than 63 of 77 live
Registered
224th of 224
by date

Among the 224 studies in Coronary Disease with a site in China, this one is the 140th largest by planned enrollment of the 142 interventional ones that give a count, is one of 16 that started in 2026, is one of 87 with no phase, reaches primary completion later than 63 of the 77 other live ones, and was the 224th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 168 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

69 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

64 more — sign in →

All 69 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

This study will assess whether planned coronary angiography (CAG), and simple percutaneous coronary intervention (PCI) when needed, can be completed safely and technically while participants are in a semi-sitting position with the head of the procedure table raised to 60 degrees. Ten clinically stable adults scheduled for an elective procedure are planned. The first stage will include participants undergoing CAG. After a safety review, the study may include participants expected to need only simple PCI. Heart rhythm, blood pressure, and blood oxygen will be monitored continuously. If predefined safety criteria occur, staff will lower the table or return the participant to a flat position and provide usual clinical care. Researchers will describe procedure completion, image quality, radiation exposure, contrast use, tolerance of the position, and safety events through 3 days after the procedure. This exploratory study is not designed to establish treatment efficacy.

Read the detailed description

This is a prospective, single-center, open-label, single-arm, staged early-feasibility study at Zhongshan Hospital, Fudan University. The planned enrollment is 10 participants aged 18 to 75 years. Eligible participants are clinically stable and scheduled for elective transradial CAG or planned simple PCI, and can tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure. The first stage prioritizes CAG. Participants expected to need only simple PCI may be enrolled only after a safety review confirms that the workflow is executable without unacceptable risk. During CAG and, when clinically indicated, simple PCI, the procedure table will be raised to a default head elevation of 60 degrees. ECG, blood pressure, and oxygen saturation will be monitored continuously. If chest pain, significant dyspnea, persistent oxygen saturation below 90%, systolic blood pressure below 90 mmHg or a decrease of at least 30% requiring intervention, sustained ventricular tachycardia or fibrillation, cerebral hypoperfusion, equipment collision, catheter or tubing traction, or another predefined safety concern occurs, the positioning intervention will stop and the table will be lowered or the participant returned to 0-degree supine; usual clinical care will take priority. CAG and PCI technical success will be described among participants undergoing the respective procedure. Safety events will be collected from the start of the positioning intervention through 3 days after the procedure. Other measures include image quality, completion of standard projections, fluoroscopy time, dose-area product, contrast volume, procedure duration, positioning changes, and tolerance. No investigational drug is used. The commercial angiography X-ray system is used as a carrier for the positioning intervention; the study does not modify or evaluate the device.

03

Conditions studied

  • Coronary Disease

Browse trials for

Keywords

  • Coronary angiography
  • Percutaneous coronary intervention
  • Semi-Fowler position
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years.
  2. Clinically stable and scheduled for elective coronary angiography (CAG) or planned simple percutaneous coronary intervention (PCI), with no ongoing resting ischemia.
  3. Meets clinical indications for coronary angiography or intervention, with ischemic evidence consistent with coronary artery disease based on symptoms, , or noninvasive imaging.
  4. Planned radial access; the operator expects the procedure can be performed using standard catheters and devices.
  5. Able to tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure.
  6. Body size, weight, shoulder width, and range of motion are within equipment and support-system limits, and the participant can be secured using the manufacturer-approved fixation system.
  7. Able to understand the study and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding, or the participant or spouse plans pregnancy within the next 6 months.
  2. Known to local anesthetic or history of severe contrast-media allergy.
  3. Neurologic or psychiatric disease or language impairment that prevents effective communication or cooperation.
  4. Serious comorbidity with expected survival less than 6 months.
  5. Uncontrolled hypertension (screening systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg) or baseline systolic blood pressure \<100 mmHg.
  6. Acute coronary syndrome, ongoing ischemia, hemodynamic instability, cardiogenic shock, or need for emergency CAG/PCI.
  7. Decompensated heart failure, \<30%, inability to maintain oxygenation at rest, or estimated \<30 mL/min/1.73 m\^2.
  8. Known or highly suspected high-risk left main disease, chronic total occlusion, complex bifurcation disease, severe calcification, or other anatomy expected to require complex PCI.
  9. count \<50 × 10\^9/L or coagulation results outside the institution usual acceptable range.
  10. Participation in another clinical trial or research study within 2 months before screening.
  11. Back pain, stiffness, limited mobility, or injury preventing tolerance of transition from supine to the study position.
  12. Inability to secure the torso reliably, inability to complete the pre-procedure positioning-tolerance test, or investigator judgment that emergency return to supine may be restricted.
  13. Any other condition for which the investigator considers participation unsafe.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Function-Friendly Semi-Fowler Positioning

    All participants receive the same positioning intervention during elective transradial CAG and, if clinically indicated, simple PCI. The procedure table is raised to a default head elevation of 60 degrees, with continuous ECG, blood pressure, and oxygen saturation monitoring. If predefined safety concerns occur, the table angle is lowered or the participant is returned to 0-degree supine and usual clinical care is provided.

    Other: Function-Friendly Semi-Fowler Positioning

Interventions

  • OtherFunction-Friendly Semi-Fowler Positioning

    The procedure table head is elevated to a default 60-degree semi-Fowler position during elective transradial coronary angiography and, if clinically indicated, simple PCI. ECG, blood pressure, and oxygen saturation are continuously monitored. If predefined safety criteria occur, the table angle is reduced or the participant is immediately returned to 0-degree supine and usual clinical care is provided. The commercial angiography X-ray system and adjustable procedure table are used as available clinical equipment; no device hardware, software, collision protection, interlocks, image processing, or dose-control functions are modified or evaluated.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Coronary Angiography (CAG) Technical Success

    The number of participants undergoing CAG who complete the planned CAG in the prespecified semi-Fowler position without position-related unplanned return to supine or substantial angle reduction, procedure discontinuation, access-site change, missing key projections, or participant/equipment collision, and whose images are independently confirmed to be diagnostic, divided by the number of participants undergoing CAG.

    Time frame: During the CAG procedure

  2. Proportion of Participants With Percutaneous Coronary Intervention (PCI) Technical Success

    Among participants who undergo PCI, the proportion who complete planned device delivery, treatment, and withdrawal while meeting the protocol-defined positioning and safety requirements. PCI success is calculated using participants who undergo PCI as the denominator.

    Time frame: During the PCI procedure

  3. Participants With Position-Related Serious Adverse Events or Prespecified Safety Events

    Number and proportion of participants experiencing a position-related serious adverse event or any prespecified safety event: hemodynamic instability, hypoxia, sustained arrhythmia, cerebral hypoperfusion, unplanned respiratory or circulatory support, mechanical collision, or emergency return to supine.

    Time frame: From the start of the positioning intervention through 3 days after the procedure

Secondary outcomes

  1. Diagnostic Acceptability of Coronary Angiography Images

    Coronary angiography and fluoroscopy image quality rated on a 1-to-3 Likert scale; a score of 2 or 3 is acceptable. Images are assessed by two independent physicians, with adjudication by a third if needed.

    Time frame: During the procedure

  2. Completion of Standard Coronary Angiographic Views and Visualization of Major Coronary Segments

    Completion of standard left anterior oblique, right anterior oblique, cranial, and caudal projections, and the ability to visualize the left anterior descending, left circumflex, and right coronary arteries and their major branches.

    Time frame: During the procedure

  3. Total Fluoroscopy Time

    Total fluoroscopy time recorded during the CAG and, if performed, PCI procedure.

    Time frame: During the procedure

  4. Dose-Area Product (DAP)

    Dose-area product and other radiation dose parameters recorded by the angiography system.

    Time frame: During the procedure

  5. Contrast Volume

    Total contrast-media volume administered during the procedure.

    Time frame: During the procedure

  6. Procedure Duration

    Total duration of the CAG procedure and, if performed, PCI procedure, recorded as specified in the study CRF.

    Time frame: During the procedure

  7. Positioning Tolerance and Adjustments

    Table-head angle, number and reasons for position adjustments, participant symptoms, unplanned return to 0-degree supine, and equipment collision events.

    Time frame: During the procedure

  8. Access and Device Delivery Completion

    Successful radial artery access and completion of planned device delivery and withdrawal, as applicable to the procedure performed.

    Time frame: During the procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — The protocol states that any data sharing must use de-identified data and receive the required approvals. Whether individual participant data will be shared, and the timing, access process, and supporting information, have not yet been determined.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 18 months is below that.

Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
May 2028
CompletionEst.
Nov 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944716
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Cong Wang
Contact
kelindunzizhuan@126.com
+86 13671683698
Junbo Ge
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion